Ophthalmic Adaptive Optics (AO) Retinal Imaging System

Back to opportunities

CombinedTotal Small Business Set-Aside (FAR 19.5)1

Ophthalmic Adaptive Optics (AO) Retinal Imaging System

HEALTH AND HUMAN SERVICES, DEPARTMENT OF › FDA OFFICE OF ACQ GRANT SVCS

Posted Jun 2, 2026

Due Jun 16, 2026

Silver Spring, MD

NAICS 334516

Sol # RFQ-FDA-133666

AI Summary

• The FDA OSEL DBP requires an Ophthalmic Adaptive Optics Retinal Imaging System for research and development at White Oak Campus.
• This acquisition is unrestricted in nature under NAICS 542911 (Research and Development for Medical Products).
• Delivery must be made to 10903 New Hampshire Avenue, Room G101, Silver Spring, MD 20993.
• The anticipated period of performance covers the duration of the research projects.

Description

The Food and Drug Administration (FDA), Center for Devices and Radiological Health (CDRH), Office of Science and Engineering Laboratories (OSEL), Division of Biomedical Physics (DBP) intends to acquire one (1) Ophthalmic Adaptive Optics (AO) Retinal Imaging System. The system will be used to support retinal imaging research, biomarker development, and regulatory science activities at the FDA White Oak Campus in Silver Spring, Maryland. Delivery and installation shall be made to 10903 New Hampshire Avenue, Building WO62, Room G101, Silver Spring, MD 20993. For complete requirements, terms, and conditions, please refer to the attached Combined Synopsis/Solicitation (CSS) document No. RFQ-FDA-133666 .

Classification

NAICS334516

PSC Code6640

Place of Performance

CitySilver Spring

StateMD

ZIP20993

CountryUNITED STATES

Contracting Office

OfficeFDA OFFICE OF ACQ GRANT SVCS

CityRockville

StateMD

ZIP20852

Contacts

Freshta Javid

freshta.javid@fda.hhs.gov

13017960385

Sarah Hussain(secondary)

Sarah.Hussain@fda.hhs.gov

Attachments (1)

Attachment 1